stonks4u
Sign up free
ENSC logo

ENSC Ensysce Biosciences, Inc.

NASDAQ Capital Market · Biotechnology · Healthcare

$0.40
+0.05 (+14.75%)

Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs d…

Market Cap: $6.14Mwww.ensysce.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

100
100
Aug 13Aug 13

Quote

Day Range
$0.34 – $0.47
52-Week Range
$0.23 – $2.75
Volume
$17.12M
Market Cap
$6.14M
50-Day Avg
$0.30
200-Day Avg
$0.72
Prev Close
$0.35
Open
$0.34

Valuation & Ratios

P/E Ratio
-0.23
EPS
$-3.98
P/B Ratio
0.73
P/S Ratio
0.00
Debt/Equity
0.10
Current Ratio
1.59
Dividend Yield
+0.0%
Gross Margin
+0.0%

Returns & Efficiency

Return on Equity
-316.6%
Return on Assets
-136.5%
FCF Yield
-337.1%
EV/EBITDA
0.16

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$0.00$-10.18M$-3.98
2024$0.00$-7.99M$-4.57
2023$0.00$-10.61M$-4.69
2022$0.00$-24.17M$-139.44
2021$0.00$-29.08M$-355.68

Social Signal Score

50
5d
50
1 mentions
—
30d
50
1 mentions
—
60d
50
1 mentions
—
90d
50
1 mentions
—
news: 1

Earnings

Fri, Nov 13(in 3 months)

Consensus estimate $0.04 per share

5of 7 quarters beat consensus

Typical surprise +28.8% (median, so one quarter with a near-zero estimate can't distort it)

  • Thu, Aug 13$-0.20 vs $-0.50beat
  • Fri, May 15$-0.52 vs $-0.73beat
  • Mon, Mar 30$-0.75 vs $-1.26beat
  • Fri, Nov 14$-1.29 vs $-0.85miss
  • Wed, Aug 13$-0.79 vs $-1.02beat
  • Tue, May 13$-1.39 vs $-3.02beat

Estimates and results for ENSC via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

ENSChas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • Newsaccessnewswire.com·1d ago·Neutral

    …y to host a Corporate Update Call on Tuesday, August 18, 2026, at 11:00 a.m. ET SAN DIEGO, CA / ACCESS Newswire / August 13, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on complex pain, today reported financial and operational results for the second quarter ended June 30, 2026.

    View source ↗